Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01494142 · ClinicalTrials.gov registry record
Registry for the Atopic Dermatitis Research Network
A clinical trial, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- 3,387
- Enrollment target
NCT01494142: Completed study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT01494142 is a clinical trial that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 3,387 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01494142 has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- 3,387 participants
- Enrollment target
Study Summary
The purpose of this multi-center, clinical registry study is to determine genetic markers associated with susceptibility of AD patients to infections and to also serve as a potential participant database for future studies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,387 participants |
| Start Date | 2011-08 |
| Est. Completion | 2018-02-07 |
What the finished NCT01494142 record still lists
NCT01494142 is an observational study that tracks outcomes without assigning an intervention. Its 3,387 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01494142 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01494142 about?
NCT01494142 is a clinical study titled "Registry for the Atopic Dermatitis Research Network". The purpose of this multi-center, clinical registry study is to determine genetic markers associated with susceptibility of AD patients to infections and to also serve as a potential participant database for future studies.
What is the current status of trial NCT01494142?
This trial is currently completed. The enrollment target is 3,387 participants. The study started on 2011-08. Estimated completion is 2018-02-07.
Who is sponsoring clinical trial NCT01494142?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06880055 · 3,375 participants
Shield Post-Approval Study Protocol
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia